Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from CytoDyn ( (CYDY) ) is now available.
On April 30, 2026, CytoDyn planned to host an investor call and webcast to deliver a corporate and clinical update centered on its leronlimab development program, supported by presentation materials also posted on its website. The company highlighted encouraging preliminary data from the Phase 2 CLOVER study in third-line microsatellite stable metastatic colorectal cancer, where leronlimab combined with Avastin and Lonsurf showed a favorable safety profile, early circulating tumor DNA declines, tumor shrinkage or stable disease in most evaluable patients, and signs of increased PD-L1 expression, potentially strengthening its positioning in the competitive solid tumor oncology market and offering early signals of clinical benefit for patients.
CytoDyn also emphasized the clinical leadership behind the program, including CEO Jacob Lalezari, who has nearly two decades of experience with leronlimab, and CFO Robert Hoffman, an industry veteran, along with principal investigator Dr. Pashtoon Kasi of City of Hope, who presented early CLOVER data at the American Association for Cancer Research Annual Meeting in April 2026. These developments suggest that, while still early-stage and subject to regulatory and funding risks, leronlimab could emerge as a differentiated CCR5-targeting option in metastatic colorectal cancer if subsequent trial phases confirm the preliminary efficacy and safety signals observed to date.
More about CytoDyn
CytoDyn Inc., listed on the OTC markets under the ticker CYDY, is a biotechnology company focused on developing leronlimab, a novel CCR5-targeting therapeutic candidate in immuno-oncology. The drug has been evaluated across more than 20 clinical studies in over 1,600 patients and is being positioned for use in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors, including as a stand-alone therapy and in combination with immune checkpoint inhibitors.
Average Trading Volume: 1,817,682
Technical Sentiment Signal: Buy
Current Market Cap: $423.5M
For detailed information about CYDY stock, go to TipRanks’ Stock Analysis page.